Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK40118 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two phase: Phase Ia is dose escalation phase and Phase Ib is dose expansion phase.

Timeline

Start

2023-03-27

Primary completion

2025-08-30

Completion

2027-06-07

Drugs

Indications